TICKERNERD
Menu
OBIOOBIOHealthcare · Biotechnology

OBIO Stock Forecast: Orchestra Biomed Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$5.73
+1.24% on the day

The 7 Wall Street analysts covering Orchestra Biomed Holdings, Inc. hold a median 12-month price target of $11 — +92.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$340.2M
Ticker Nerd rank
43 / 100
Median analyst target
$11
Analysts covering
7
Revenue$88K−89.5% y/y
Operating income−$22.4M
Net income−$23.8M
Free cash flow−$19.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.8%
1M
+5.5%
YTD
+38.1%
1Y
+97.6%
From 52W high
−9.8%
From 52W low
+99.7%
$2.87
$6.35
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

OBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Orchestra Biomed Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
43 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
98
Momentum
95
Size
59
Revisions
58
Volatility
48
Accruals
27
Value
24
Quality
22
Issuance
6

Growth (98): Sales and profits are climbing, and climbing faster than before.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

OBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on OBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00Jan 26Apr 26Jul 26Oct 26OBIOHigh $20Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $9Median $11High $20

The green dot is the last close — the median target sits +92.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
15 Sept 2026B. Riley SecuritiesMaintainsBuy$10 → $11
10 Sept 2026BTIGUpgradeBuy$10
11 Aug 2026Piper SandlerReiteratesOverweight—
11 Aug 2026Piper SandlerReiteratesOverweight$9.00 → $10
19 May 2026B. Riley SecuritiesMaintainsBuy$12 → $10
19 May 2026B. Riley SecuritiesMaintainsBuy—
14 May 2026HC Wainwright & Co.ReiteratesBuy$10
14 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026BarclaysMaintainsOverweight$12 → $13
13 May 2026BarclaysMaintainsOverweight—
12 Mar 2026Chardan CapitalMaintainsBuy—
9 Jan 2026BarclaysMaintainsOverweight—
10 Dec 2025TD CowenInitiatesBuy—
13 Nov 2025Chardan CapitalMaintainsBuy—
12 Nov 2025BarclaysMaintainsOverweight—
4 Sept 2025HC Wainwright & Co.MaintainsBuy—
20 Aug 2025BTIGDowngradeNeutral—
13 Aug 2025Chardan CapitalMaintainsBuy—
7 Aug 2025Chardan CapitalMaintainsBuy—
13 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OBIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

OBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Orchestra Biomed Holdings, Inc. returned +97.6% against +16.2% for the S&P 500, dividends included.

OBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200220Jan 26Apr 26Jul 26Oct 26OBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

OBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Orchestra Biomed Holdings, Inc. (OBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.1×

Cheaper than 90% of US stocks

Price / sales
10.6×

Cheaper than 14% of US stocks

Price / book
17.6×

Cheaper than 5% of US stocks

EV / EBITDA
−5.6×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−89.5%

Higher than 2% of US stocks

Earnings growth (YoY)
−89.5%

Higher than 4% of US stocks

Gross margin
71.6%

Higher than 84% of US stocks

Operating margin
−25404.5%

Higher than 1% of US stocks

Net margin
−184.6%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−397.3%

Higher than 4% of US stocks

Return on assets
−45.7%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Orchestra Biomed Holdings, Inc. (OBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Orchestra Biomed Holdings, Inc. has a market value of $340.2M and an enterprise value of $321.9M.

  • Revenue in the twelve months to 30 June 2026: $32.0M. The latest quarter shrank 89.5% year on year.

  • Net income over the same four quarters: −$59.0M, a −184.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$59.1M.

  • Shares outstanding: 60.1M.

  • Trailing P/E: −5.1×; forward P/E: −3.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Orchestra Biomed Holdings, Inc. employs 86 people — $372K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

OBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
OBIOOrchestra Biomed Holdings, Inc.$340.2M
43
TTRXTurn Therapeutics, Inc.$335.4M
19
AGENAgenus, Inc.$337.4M
87
RLMDRelmada Therapeutics, Inc.$332.5M
64
OCGNOcugen, Inc.$330.9M
21
ARTVArtiva Biotherapeutics, Inc.$330.4M
33
SRZNSurrozen, Inc.$321.3M
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Orchestra Biomed Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest OBIO news & analysis

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

GlobeNewsWire · 1 Oct 2026positive

Orchestra BioMed announced it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial of AVIM Therapy, with 330 patients randomized as of September 30, 2026, exceeding the prior target of 316. The company reiterated that primary endpoint data will be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027, and the data is expected to support marketing application submissions by Medtronic to the FDA and other regulatory agencies.

Why it matters — Surpassing the enrollment target is a key trial milestone that moves the AVIM therapy forward toward potential regulatory submissions by Medtronic and a major cardiovascular conference presentation in Q2 2027.

OBIO's Capital Access Advisory Program (CAAP®) Reaches Milestone with $1 Billion Raised by High-Growth Life Sciences and Health Tech Ventures

Business Wire · 29 Sept 2026positive

OBIO announced that companies supported through its Capital Access Advisory Program (CAAP) have collectively raised over $1 billion in capital, marking a milestone for the program. The funding has been raised by high-growth life sciences and health tech ventures.

Why it matters — This milestone signals growing success and traction for OBIO's advisory program, which could reflect positively on the organization's standing and reach within the life sciences and health tech sectors.

Strength Seen in Orchestra BioMed Holdings, Inc. (OBIO): Can Its 5.2% Jump Turn into More Strength?

Zacks Investment Research · 21 Sept 2026positive

Orchestra BioMed Holdings, Inc. (OBIO) saw its share price rise by 5.2% in the last trading session on above-average trading volume. The article notes that the latest trend in earnings estimate revisions for the stock suggests possible continued strength ahead.

Why it matters — A OBIO watcher would care because the rising share price, strong trading volume, and positive earnings estimate revision trend may signal growing investor confidence in the company.

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

GlobeNewsWire · 16 Sept 2026positive

Orchestra BioMed announced that its investigational AVIM Therapy will be featured in two sessions at HRX Live 2026, the Heart Rhythm Society's annual innovation-focused meeting, held September 18-20, 2026, in Atlanta, Georgia.

Why it matters — A watcher would see this as notable because AVIM Therapy, a key investigational product in the company's pipeline, is gaining recognition and visibility at a major industry innovation meeting.

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

GlobeNewsWire · 15 Sept 2026positive

Orchestra BioMed announced receipt of a $6.1 million milestone payment on September 14, 2026, the first payment tied to Haemonetics' acquisition of Vivasure. Combined with roughly $5 million received in January 2026, total cash proceeds are approximately $11 million, with up to about $10 million more potentially available through future revenue earnouts.

Why it matters — The monetization of this strategic holding provides additional capital to fund Orchestra BioMed's pivotal programs and reflects its approach to creating value through partnerships.

FAQ

Frequently asked questions about OBIO stock

What is the OBIO stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Orchestra Biomed Holdings, Inc. have a median 12-month price target of $11, with estimates ranging from $9 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is OBIO stock a buy right now?

Of the 7 analysts covering Orchestra Biomed Holdings, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Orchestra Biomed Holdings, Inc. 43 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank OBIO?

As at 8 Oct 2026, Orchestra Biomed Holdings, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (98 of 100).

Will OBIO stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +92.0% from the last close, and Ticker Nerd's factor model ranks Orchestra Biomed Holdings, Inc. 43 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the OBIO stock forecast for 2030?

No analyst covering Orchestra Biomed Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $20 over the next 12 months.

How has OBIO stock performed over the past year?

Orchestra Biomed Holdings, Inc. returned +97.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Orchestra Biomed Holdings, Inc. do?

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions.

What is the latest news on OBIO?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy". Orchestra BioMed announced it has surpassed full enrollment in the BACKBEAT Global Pivotal Trial of AVIM Therapy, with 330 patients randomized as of September 30, 2026, exceeding the prior target of 316. The company reiterated that primary endpoint data will be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027, and the data is expected to support marketing application submissions by Medtronic to the FDA and other regulatory agencies.

Company

About Orchestra Biomed Holdings, Inc.

Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on developing therapeutic technologies for cardiovascular disease and related medical conditions. Its current portfolio centers on AVIM Therapy, a bioelectronic treatment candidate designed to help lower blood pressure in patients with pacemakers, and Virtue Sirolimus AngioInfusion Balloon, a drug-device platform intended for treating atherosclerotic artery disease. The company also works on cardiac neuromodulation programs and minimally invasive device technologies that support interventional procedures. Orchestra BioMed’s business model relies on partnerships with established medical device companies to advance clinical development and commercialization. Headquartered in New Hope, Pennsylvania, Orchestra BioMed plays a niche role in the medical technology market by combining device innovation, bioelectronic therapy, and targeted drug delivery within cardiovascular care.

CEO Mr. David P. Hochman · 86 employees · United States · https://www.orchestrabiomed.com